semaglutide expected launch date Real Review,semaglutide in 2026 or 2027

The landscape of diabetes and weight management treatments is rapidly evolving, with semaglutide at the forefront of innovation. As many anticipate new formulations and wider accessibility, understanding the semaglutide expected launch date for various markets is crucial. Recent developments, particularly concerning patent expiries and new product approvals, are shaping the coming months and years for this transformative medication.

Global Market Entry and Patent Expiries:

A significant driver for the semaglutide expected launch date is the expiration of patents held by the original manufacturer, Novo Nordisk. While semaglutide has been available since 2017, with Ozempic receiving FDA approval for diabetes, its patent protection is gradually diminishing in key regions. In India, for instance, the patent expiry in mid-March 2026 has already paved the way for a surge in generic versions. As of 21 March 2026, multiple generic semaglutide products have officially launched in the Indian market, with companies like Reddy's and Lupin preparing near-immediate launches. This marks a substantial shift, with over 40 drugmakers in India now expected to offer their own versions of semaglutide in the coming weeks and months, with some expecting to offer their injectable versions at competitive prices, potentially starting around 1,290 rupees per unit.

Globally, while patents extend into the early 2030s in many countries, some are slated to expire starting in 2026. This anticipation of patent expiry is fueling the development and planned launch of generic semaglutide in various markets, including Mexico and Saudi Arabia by companies like Biocon.

Oral Formulations and New Product Launches:

Beyond generics, the development of oral formulations of semaglutide is a major area of focus, significantly influencing the semaglutide expected launch date. Novo Nordisk has made significant strides in this area. The Ozempic pill, an oral formulation of semaglutide, received FDA approval and was expected to launch in the US in early January 2026. This once-daily oral semaglutide medication is now available by prescription in the US, marking a new era for GLP-1 receptor agonists. Furthermore, Novo Nordisk's Wegovy pill, the first weight-loss drug of its kind to win agency approval, was also expected to launch in the US in early 2026. The Wegovy pill is currently approved in the US, with Novo Nordisk aiming for a launch in the second quarter of 2026 (Q2 2026) in the US market. A 25-mg dose of Ozempic tablets is anticipated to receive a decision from health regulators by the end of 2026, with Novo Nordisk aiming for a launch in the second quarter of 2026 (Q2 2026) in the US market.

The approval of oral semaglutide has also extended to cardiovascular benefits, further solidifying its therapeutic value. This oral pill, priced at approximately $149 per month, became available in early January 2026.

Future Projections and Emerging Treatments:

The pipeline for GLP-1 receptor agonists is robust, with further innovations anticipated. CagriSema (a combination of cagrilintide and semaglutide) is a promising candidate, with an FDA response expected sometime in 2026. While a US market launch for CagriSema is expected in 2027, given regulatory processes. Eli Lilly is also actively developing new GLP-1 pills, with potential launches expected as early as late 2028. Another development, MariTide, has its phase three trials scheduled to report in 2027, suggesting a potential availability no earlier than 2029 if approved.

Looking ahead, the UK market may see new weight-loss injections as soon as late 2026 or early 2027, following the approval process. The fourth quarter of 2025 was a key period for decisions regarding oral Wegovy for weight management, which would make it the first oral GLP-1 formulation for chronic weight management.

In summary, the semaglutide expected launch date varies significantly by region and formulation. While India has already seen a substantial influx of generic semaglutide in March 2026, the US market is witnessing the launch of oral versions of Ozempic and Wegovy in early 2026. The coming years promise further advancements in GLP-1 therapies, with ongoing research and development aimed at improving patient outcomes for diabetes and weight management. The **semaglutide patent expiry